Table 10.
Effects of theaflavins in esophageal cancer, stomach cancer and fibrosarcoma.
| Cell Line/Animal Model | Treatment | Effects | Reference |
|---|---|---|---|
| Eca-109 | 50 µM TF3 24 h |
↑Apoptosis ↑Caspase-3 and -9 activity |
[33] |
| KATO III | 0–1 mg/mL theaflavin extract; 1–3 days 0–1.5 mM TF3; 1–3 days 0–2 mM TF1; 1–3 days |
↑Apoptosis ↑Apoptotic bodies ↑DNA fragmentation |
[65] |
| MKN-28 | 3.9, 16, 63, 250, 100 µg/mL TF1 TF2b, and TF3 | ↓Proliferation | [39] |
| H1080 | TF1 0.8–100 µg/mL 5–18 h |
↓Invasion ↓Cell Viability ↓MMP-9 and -2 activity |
[66] |
Legend: ↑, increase; ↓, decrease.